

*Response and Amendment*

U.S. Serial No. 09/843,167

Atty Reference: 007426/0266891

Page 4

**Remarks**

The non-elected claims have been cancelled without prejudice of disclaimer. Claim 18 has been amended to recite amide derivatives, supported by Examples 3, 4 and 5. No new matter has been added.

The claims are now in condition for examination. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, he is kindly requested to contact the undersigned at the telephone number listed below.

All objections and rejections having been addressed, it is respectfully submitted that the present application is in a condition for allowance and a Notice to that effect is earnestly solicited.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

Robert W. Hahl, Ph.D.

Registration No. 33,893

Paul L. Sharer

Registration No. 36,004

RWH/

1600 Tysons Boulevard

McLean, Virginia 22102

(703) 905-2000 Telephone

(703) 905-2500 Facsimile

Date: September 30, 2002

Attorney Reference: 007426/0266891


Attachment: Appendix

Information Disclosure Statement


**Appendix: Version to Show Changes Made to Specification**

**In the Claims:**


18 (Amended). A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound according to the formula 1:



wherein Z is



H; A''; B''; or



n, m, q and r are independently integers from zero to 4 provided that  $n + m \leq 4$  and  $q + r \leq 4$ ; p and s are independently integers from zero to 5 provided that  $p + s \leq 5$ ; a, b and c are double bonds which may be present or absent; when present, the double bonds may be in the E or Z

*Response and Amendment*

U.S. Serial No. 09/843,167

Atty Reference: 007426/0266891

Page 6

configuration and, when absent, the resulting stereocenters may have the R- or S- configuration;

[R, R' and R'' are independently H, C<sub>1</sub>-C<sub>20</sub> linear or branched alkyl, C<sub>2</sub>-C<sub>20</sub> linear or branched alkenyl, -CO<sub>2</sub>Z', wherein Z' is H, sodium, potassium, or other pharmaceutically acceptable counter-ion such as calcium, magnesium, ammonium, tromethamine, tetramethylammonium, and the like; -CO<sub>2</sub>R''', -NH<sub>2</sub>, -NHR''', -NR<sub>2</sub>'', -OH, -OR''', halo, substituted C<sub>1</sub>-C<sub>20</sub> linear or branched alkyl or substituted C<sub>2</sub>-C<sub>20</sub> linear or branched alkenyl, wherein R''' is independently C<sub>1</sub>-C<sub>20</sub> linear or branched alkyl, linear or branched alkenyl;]

R and R' are independently H, C<sub>1</sub>-C<sub>20</sub> linear or branched alkyl, C<sub>2</sub>-C<sub>20</sub> linear or branched alkenyl, -CO<sub>2</sub>Z', wherein Z' is H, sodium, potassium, or other pharmaceutically acceptable counter-ion such as calcium, magnesium, ammonium, tromethamine, tetramethylammonium, and the like; -CO<sub>2</sub>R''', -NH<sub>2</sub>, -NHR''', -NR<sub>2</sub>'', -OH, -OR''', halo, substituted C<sub>1</sub>-C<sub>20</sub> linear or branched alkyl or substituted C<sub>2</sub>-C<sub>20</sub> linear or branched alkenyl, wherein R''' is independently C<sub>1</sub>-C<sub>20</sub> linear or branched alkyl, linear or branched alkenyl or aralkyl -(CH<sub>2</sub>)<sub>x</sub>-Ar, where x is 1-6; CONR<sub>2</sub>'''', where R'''' is independently H, optionally substituted C<sub>1</sub>-C<sub>20</sub> alkyl, optionally substituted C<sub>2</sub>-C<sub>20</sub> alkenyl or optionally substituted C<sub>6</sub>-C<sub>10</sub> aryl or where NR<sub>2</sub>''' represents a cyclic moiety;

R'' is independently H, C<sub>1</sub>-C<sub>20</sub> linear or branched alkyl, C<sub>2</sub>-C<sub>20</sub> linear or branched alkenyl, -CO<sub>2</sub>Z', wherein Z' is H, sodium, potassium, or other pharmaceutically acceptable counter-ion such as calcium, magnesium, ammonium, tromethamine, tetramethylammonium, and the like; -CO<sub>2</sub>R''', -NH<sub>2</sub>, -NHR''', -NR<sub>2</sub>'', -OH, -OR''', halo, substituted C<sub>1</sub>-C<sub>20</sub> linear or branched alkyl or substituted C<sub>2</sub>-C<sub>20</sub> linear or branched alkenyl, wherein R''' is independently C<sub>1</sub>-C<sub>20</sub> linear or branched alkyl, linear or branched alkenyl or aralkyl -(CH<sub>2</sub>)<sub>x</sub>-Ar, where x is 1-6;

A, A' and A'' are independently H, C<sub>1</sub>-C<sub>20</sub> acylamino;

C<sub>1</sub>-C<sub>20</sub> acyloxy; C<sub>1</sub>-C<sub>20</sub> alkanoyl;

C<sub>1</sub>-C<sub>20</sub> alkoxycarbonyl; C<sub>1</sub>-C<sub>20</sub> alkoxy;

C<sub>1</sub>-C<sub>20</sub> alkylamino; C<sub>1</sub>-C<sub>20</sub> alkylcarboxylamino; carboxyl; cyano; halo; hydroxy;

*Response and Amendment*

U.S. Serial No. 09/843,167

Atty Reference: 007426/0266891

Page 7

B, B' and B'' are independently H;

C<sub>1</sub>-C<sub>20</sub> acylamino; C<sub>1</sub>-C<sub>20</sub> acyloxy; C<sub>1</sub>-C<sub>20</sub> alkanoyl;

C<sub>1</sub>-C<sub>20</sub> alkenoyl; C<sub>1</sub>-C<sub>20</sub> alkoxycarbonyl;

C<sub>1</sub>-C<sub>20</sub> alkoxy; C<sub>1</sub>-C<sub>20</sub> alkylamino;

C<sub>1</sub>-C<sub>20</sub> alkylcarboxylamino; aroyl, aralkanoyl; carboxyl; cyano; halo; hydroxy; nitro;

optionally substituted, linear or branched C<sub>1</sub>-C<sub>20</sub> alkyl or C<sub>2</sub>-C<sub>20</sub> alkenyl;

or A and B together, or A' and B' together, or A'' and B'' together, maybe joined to form a methylenedioxy or ethylenedioxy group; and

X, X' are independently -NH, -NR'', O or S, in a physiologically acceptable carrier.